What is the initial treatment approach for hyperphosphatemia in a patient with Tumor Lysis Syndrome (TLS) and impaired renal function?

Treatment of Hyperphosphatemia in Tumor Lysis Syndrome

Mild hyperphosphatemia (<1.62 mmol/L or <5 mg/dL) does not require treatment, but levels above this threshold should be treated with aluminum hydroxide at 50-100 mg/kg/day divided into 4 doses, administered orally or by nasogastric tube. 1

Initial Management Approach

Aggressive Hydration as Foundation

• Maintain urine output at minimum 100 mL/hour (3 mL/kg/hour in children <10 kg) through central venous access 1
• Loop diuretics (or mannitol) may be required to achieve target urine output, except in patients with obstructive uropathy or hypovolemia 1
• Hydration should ideally start 48 hours before tumor-specific therapy when possible 1

Phosphate Binder Therapy

• Aluminum hydroxide 50-100 mg/kg/day divided in 4 doses is the recommended phosphate binder for hyperphosphatemia >1.62 mmol/L 1
• Can be administered orally or via nasogastric tube 1
• Alternative phosphate binders like sevelamer may be considered, though aluminum hydroxide remains the guideline-recommended agent 2, 3

Critical Threshold for Dialysis

When Renal Replacement Therapy Becomes Necessary

Early initiation of renal replacement therapy should be strongly considered when:

• Phosphate levels rapidly rise and exceed 5 mmol/L (15.5 mg/dL) 4
• Severe hyperphosphatemia persists despite phosphate binders 3, 5
• Oliguria develops unresponsive to diuretics 1
• Creatinine exceeds 200 μmol/L (2.26 mg/dL) 4
• Concurrent severe hyperkalemia (>6 mmol/L) or metabolic acidosis develops 1, 4

The threshold for RRT initiation in TLS is lower than other clinical situations because cell breakdown is ongoing and rapid electrolyte increases cannot be predicted 3

Dialysis Modality Selection

• Intermittent hemodialysis (IHD) is highly effective for phosphate removal, with clearance rates allowing 50% reduction in 6-hour treatments 1
• Continuous renal replacement therapy (CRRT) provides superior hemodynamic stability and better control of azotemia and fluid overload compared to IHD 1
• Consider combination therapy: IHD for rapid initial phosphate reduction followed by CRRT to prevent rebound hyperphosphatemia 6
• Peritoneal dialysis is rarely used due to lower efficiency in removing phosphate and should be avoided 1

Important Clinical Pitfalls

Rebound Hyperphosphatemia

• Phosphate levels can rebound immediately after hemodialysis due to ongoing tumor cell lysis 6
• CVVH following hemodialysis maintains stable phosphate levels until renal function improves 6
• More frequent dialysis treatments may improve outcomes in TLS with kidney damage 1

Calcium Administration Caution

• Do NOT treat asymptomatic hypocalcemia 1
• High phosphate concentrations combined with calcium administration can precipitate calcium-phosphate complexes in renal interstitium and tubular system, exacerbating kidney damage 1
• Only administer calcium gluconate 50-100 mg/kg for symptomatic hypocalcemia (tetany, seizures), and repeat cautiously if necessary 1

Rasburicase Era Considerations

• Despite excellent uric acid control with rasburicase, massive hyperphosphatemia can still develop and cause acute kidney injury 5
• In the rasburicase era, hyperphosphatemia has become the key target for preventing and treating TLS 5
• Renal replacement therapy remains the only truly effective option for rapidly lowering severe hyperphosphatemia 5

Monitoring Requirements

• Check phosphate, potassium, calcium, uric acid, and creatinine every 6 hours until normalized 7
• Perform careful ECG monitoring in hyperkalemic patients 1
• High serum phosphate and calcium-phosphate complexes are the primary mechanisms exacerbating kidney damage in TLS 1